Source:http://linkedlifedata.com/resource/pubmed/id/12777472
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2003-7-24
|
pubmed:abstractText |
Recent studies showed lower apolipoprotein A-IV (apoA-IV) plasma concentrations in patients with coronary artery disease (CAD). The actual distribution of the antiatherogenic apoA-IV in human plasma, however, is discussed controversially and it was never investigated in CAD patients. We therefore developed a gentle technique to separate the various apoA-IV-containing plasma fractions. Using a combination of precipitation of all lipoproteins with 40% phosphotungstic acid and 4 M MgCl2, as well as immunoprecipitation of all apoA-I-containing particles with an anti-apoA-I antibody, we obtained three fractions of apoA-IV: lipid-free apoA-IV (about 4% of total apoA-IV), apoA-IV associated with apoA-I (LpA-I:A-IV, 12%), and apoA-I-unbound but lipoprotein-containing apoA-IV (LpA-IV, 84%). We compared these three apoA-IV fractions between 52 patients with a history of CAD and 52 age- and sex-matched healthy controls. Patients had significantly lower apoA-IV levels when compared to controls (10.28 +/- 3.67 mg/dl vs. 11.85 +/- 2.82 mg/dl, P = 0.029), but no major differences for the three plasma apoA-IV fractions. We conclude that our gentle separation method reveals a different distribution of apoA-IV than in many earlier studies. No major differences exist in the apoA-IV plasma distribution pattern between CAD patients and controls. Therefore, the antiatherogenic effect of apoA-IV has to be explained by other functional properties of apoA-IV (e.g., the antioxidative characteristics).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0022-2275
|
pubmed:author |
pubmed-author:AlberHannes FHF,
pubmed-author:DieplingerHansH,
pubmed-author:EzehBenjieB,
pubmed-author:HaimanMarinaM,
pubmed-author:KraftHans-GeorgHG,
pubmed-author:KronenbergFlorianF,
pubmed-author:KunzBirgitB,
pubmed-author:LingenhelArnoA,
pubmed-author:PachingerOtmarO,
pubmed-author:PaulweberBernhardB,
pubmed-author:WeidingerFranzF
|
pubmed:issnType |
Print
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1523-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12777472-Adult,
pubmed-meshheading:12777472-Apolipoproteins A,
pubmed-meshheading:12777472-Case-Control Studies,
pubmed-meshheading:12777472-Coronary Artery Disease,
pubmed-meshheading:12777472-Female,
pubmed-meshheading:12777472-Health,
pubmed-meshheading:12777472-Humans,
pubmed-meshheading:12777472-Immunoblotting,
pubmed-meshheading:12777472-Male,
pubmed-meshheading:12777472-Middle Aged
|
pubmed:year |
2003
|
pubmed:articleTitle |
Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls.
|
pubmed:affiliation |
Institute of Medical Biology and Human Genetics, University of Innsbruck, Schöpfstr 41, A-6020, Innsbruck, Austria.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|